GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Clinical trials for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Syfovre safety check: Real-World study tracks eye drug in 300 patients
Disease control OngoingThis study looks at how safe and tolerable the drug pegcetacoplan (Syfovre) is for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 300 patients who are already prescribed the drug by their doctor will be followed …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to slow vision loss in Age-Related blindness
Disease control OngoingThis study tests a drug called BI 1584862 in 150 adults aged 50+ with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for 1 year. Doctors track changes in the retina using special …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New eye drug aims to slow vision loss from dry macular degeneration
Disease control OngoingThis study tests an experimental drug called AVD-104, given as an eye injection, for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The trial involves 300 participants and aims to see if the drug is safe and can slow …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Aviceda Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC